Coxatab 57 mg Chewable Tablets for Dogs

None.

Special precautions for safe use in the target species:
The recommended dose, see section 3.9, should not be exceeded.
Use in very young animals, or animals with suspected or confirmed impairment of
renal, cardiac or hepatic function may involve additional risk. If such use cannot be
avoided, those dogs require careful veterinary monitoring.
Avoid use in dehydrated, hypovolaemic or hypotensive animals, as there is a
potential risk of increased renal toxicity. Concurrent administration of potentially
nephrotoxic medicinal products should be avoided.
Use this veterinary medicinal product under strict veterinary monitoring where there
is a risk of gastrointestinal bleeding, or if the animal previously displayed intolerance
to NSAIDs. Renal and/or hepatic disorders have been reported in very rare cases in
dogs administered the recommended treatment dose. It is possible that a proportion
of such cases had sub-clinical renal or hepatic disease prior to the commencement
of therapy. Therefore, appropriate laboratory testing to establish baseline renal or
hepatic biochemistry parameters is recommended prior to and periodically during
administration.
The treatment should be discontinued if any of these signs are observed: repeated
diarrhoea, vomiting, faecal occult blood, sudden weight loss, anorexia, lethargy,
degradation of renal or hepatic biochemistry parameters.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
This product may be harmful following accidental ingestion. The target organs for
toxicity in the repeat-dose toxicological studies were usually liver, brain and
gastrointestinal tract.
In order to prevent children from accessing the product, tablets should be administered
and stored out of their sight and reach. Halved or quartered tablets should be returned
to the open blister pocket and inserted into the outer carton.
In the event of accidental ingestion of one or more tablets, seek medical advice
immediately and show the package leaflet or the label to the doctor.
Laboratory studies in rats and rabbits have shown evidence that firocoxib has the
potential to affect reproduction and to induce malformations in foetuses. Pregnant
women or women who are intending to become pregnant should administer the
product with caution.
Wash hands after use of the product.
Special precautions for the protection of the environment:
Not applicable.